Raine, J., Tolwinski, N., Gruber, J., & Mathuru, A. S. (2024). Evaluating the inter-species transmission risk of amyloid beta peptide aggregates via ingestion. Alzheimer’s Research & Therapy, 16(1). https://doi.org/10.1186/s13195-024-01487-8
Abstract:
Abstract
Background
Recent reports suggest that amyloid beta (Aβ) peptides can exhibit prion-like pathogenic properties. Transmission of Aβ peptide and the development of associated pathologies after surgeries with contaminated instruments and intravenous or intracerebral inoculations have now been reported across fish, rodents, primates, and humans. This raises a worrying prospect of Aβ peptides also having other characteristics typical of prions, such as evasion of the digestive process. We asked if such transmission of Aβ aggregates via ingestion was possible.
Methods
We made use of a transgenic Drosophila melanogaster line expressing human Aβ peptide prone to aggregation. Fly larvae were fed to adult zebrafish under two feeding schemes. The first was a short-term, high-intensity scheme over 48 h to determine transmission and retention in the gut. The second, long-term scheme specifically examined retention and accumulation in the brain. The gut and brain tissues were examined by histology, western blotting, and mass spectrometric analyses.
Results
None of the analyses could detect Aβ aggregates in the guts of zebrafish following ingestion, despite being easily detectable in the feed. Additionally, there was no detectable accumulation of Aβ in the brain tissue or development of associated pathologies after prolonged feeding.
Conclusions
While human Aβ aggregates do not appear to be readily transmissible by ingestion across species, two prospects remain open. First, this mode of transmission, if occurring, may stay below a detectable threshold and may take much longer to manifest. A second possibility is that the human Aβ peptide is not able to trigger self-propagation or aggregation in other species. Either possibility requires further investigation, taking into account the possibility of such transmission from agricultural species used in the food industry.
License type:
Attribution 4.0 International (CC BY 4.0)
Funding Info:
This research / project is supported by the Ministry of Health National Medical Research Council - Healthy Longevity Catalyst Award
Grant Reference no. : MOH-000517
Description:
https://www.biomedcentral.com/getpublished/copyright-and-license
Copyright and License
When an author submits a manuscript for publishing they will need to sign a license agreement with Springer Nature to allow us to publish their article. According to this agreement:
authors of articles published in Springer Nature journals retain the copyright of their articles.
authors grant Springer Nature a license to publish the article and identify itself as the original publisher.
authors will retain broad re-use rights to their article content for their future publications.
when Springer Nature publishes the article we will apply a Creative Commons licence allowing re-use of the article by third parties for particular purposes.
You may also wish to find out about licence variations available to meet funder and institutional OA licence requirements. Learn more in our guide to licensing, copyright and author rights for journal articles.
Exceptions to copyright policy
Our policy pages provide details concerning copyright and licensing for articles which were previously published under policies that are different from the above. For instance, occasionally BMC may co-publish articles jointly with other publishers, and different licensing conditions may then apply. In all such cases, however, access to these articles is free from fees or any other access restrictions.
Information specifically regarding permissions and reprints can be found here. Please contact us if there are questions.